Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. Nyang'wa BT, et al. Among authors: spigelman m. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166. N Engl J Med. 2022. PMID: 36546625 Clinical Trial.
Mycobacterium tuberculosis: new tricks for an old bug.
Spigelman M, Ma Z. Spigelman M, et al. Expert Rev Anti Infect Ther. 2004 Aug;2(4):467-9. doi: 10.1586/14787210.2.4.467. Expert Rev Anti Infect Ther. 2004. PMID: 15482211 No abstract available.
Advancing the science in clinical trials for new TB drugs.
Burman W, McNeeley D, Moulton LH, Spigelman M, Vernon A. Burman W, et al. Among authors: spigelman m. Int J Tuberc Lung Dis. 2008 Feb;12(2):111-2. Int J Tuberc Lung Dis. 2008. PMID: 18230241 No abstract available.
Phase I study of L-alanosine (NSC 15353).
Goldsmith MA, Ohnuma T, Spigelman M, Greenspan EM, Holland JF. Goldsmith MA, et al. Among authors: spigelman m. Cancer. 1983 Feb 1;51(3):378-80. doi: 10.1002/1097-0142(19830201)51:3<378::aid-cncr2820510303>3.0.co;2-i. Cancer. 1983. PMID: 6821823
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Dawson R, et al. Among authors: spigelman m. Lancet. 2015 May 2;385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X. Epub 2015 Mar 18. Lancet. 2015. PMID: 25795076 Clinical Trial.
Tuberculosis.
Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M. Pai M, et al. Among authors: spigelman m. Nat Rev Dis Primers. 2016 Oct 27;2:16076. doi: 10.1038/nrdp.2016.76. Nat Rev Dis Primers. 2016. PMID: 27784885 Review.
Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
Tweed CD, Crook AM, Amukoye EI, Dawson R, Diacon AH, Hanekom M, McHugh TD, Mendel CM, Meredith SK, Murphy ME, Murthy SE, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Wills GH, Gillespie SH. Tweed CD, et al. Among authors: spigelman m. BMC Infect Dis. 2018 Jul 11;18(1):317. doi: 10.1186/s12879-018-3230-6. BMC Infect Dis. 2018. PMID: 29996783 Free PMC article.
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.
Tweed CD, Crook AM, Dawson R, Diacon AH, McHugh TD, Mendel CM, Meredith SK, Mohapi L, Murphy ME, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Gillespie SH. Tweed CD, et al. Among authors: spigelman m. BMC Pulm Med. 2019 Aug 14;19(1):152. doi: 10.1186/s12890-019-0907-6. BMC Pulm Med. 2019. PMID: 31412895 Free PMC article. Clinical Trial.
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Tweed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, Conradie F, Diacon AH, Ntinginya NE, Everitt DE, Haraka F, Li M, van Niekerk CH, Okwera A, Rassool MS, Reither K, Sebe MA, Staples S, Variava E, Spigelman M. Tweed CD, et al. Among authors: spigelman m. Lancet Respir Med. 2019 Dec;7(12):1048-1058. doi: 10.1016/S2213-2600(19)30366-2. Epub 2019 Nov 12. Lancet Respir Med. 2019. PMID: 31732485 Free PMC article. Clinical Trial.
124 results